Blinatumomab, targeting CD19 on B cells, is approved for the treatment of relapsed or refractory (r/r) B cell precursor acute lymphoblastic leukemia (BCP-ALL) and BCP-ALL with minimal residual disease (Goebeler and Bargou, 2016; Sun et al., 2015). Here, CD19 is linked to acute lymphoblastic leukemia.